News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
CRISPR Therapeutics (CRSP) has experienced a significant 61% decline in its stock price over the past five years, prompting an evaluation of its current valuation. Despite the sharp drop, the stock is currently assessed as being in "about right" territory rather than clearly undervalued …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%Earlier this week, CRISPR Therapeutics AG drew attention as analysts projected an earnings per share of US$1.10 loss alongside very large year-over-year revenue growth for its upcoming results. This combination of improving earnings expectations and strong sales momentum has sharpened the focus on how …
This article analyzes Crispr Therapeutics Ag (NASDAQ: CRSP), highlighting weak sentiment across all horizons which supports a short bias. It outlines an exceptional 47.4:1 risk-reward short setup targeting a 14.0% downside. The analysis also provides institutional trading strategies, including long, momentum breakout, and risk …
CRISPR Therapeutics (CRSP) shares have dropped 10.4% as the market anticipates an earnings report showing improved EPS and significant year-over-year revenue growth. Despite these positive projections, concerns persist regarding the company's operating performance, financial health, and high valuation, leading investors to re-evaluate its position. …
Ispire Technology (ISPR) has appointed Michael Wang as the CEO of its Aspire North America subsidiary. This information was disclosed in a recent SEC filing. The announcement highlights a key leadership change within the company's North American operations.
Ispire Technology (ISPR) has modified its executive structure, naming Michael Wang as CEO of Aspire North America, its subsidiary. Concurrently, Tuanfang Liu has assumed the role of sole Chief Executive Officer for Ispire Technology, effective July 16, 2026. This change reassigns Wang's former Co-Chief …
Ispire Technology Inc. has announced a leadership change, naming Tuanfang Liu as the sole Chief Executive Officer. Michael Wang, previously Co-CEO, will now serve as CEO of Aspire North America, a wholly owned subsidiary of the company. This restructuring consolidates executive responsibilities at the …
CRISPR Therapeutics AG (CRSP) experienced a decline of -1.63% in its latest trading session, underperforming the broader S&P 500. Shares have depreciated by 10.21% over the past month, trailing both the Medical sector and the S&P 500. Investors are anticipating upcoming earnings, with projected …
CRISPR Therapeutics (CRSP) stock, despite a 60% decline over five years, now appears to be at a fair valuation, not clearly cheap or expensive. With strong cash reserves of $2.4 billion and a growing gene editing pipeline, the company faces uncertainty regarding the commercial …
Search by ticker symbol or company name and select a result to open its chart.